New drug targets Hard-to-Treat lymphoma in early trial
Disease control
Recruiting now
This early-phase trial is testing a drug called tegavivint in about 18 people whose large B-cell lymphoma has come back or stopped responding to standard treatments. The drug works by blocking certain enzymes that cancer cells need to grow. The main goals are to find the safest d…
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated May 13, 2026 15:59 UTC